Identification of Risk Factors Associated with Acute Kidney Injury in Patients Taking Sodium-Glucose Cotransporter-2 Inhibitors.

The transient eGFR decline with SGLT2 inhibitor initiation should be expected and is generally not an indication to discontinue therapy. Future initiatives should be directed at increasing knowledge of monitoring recommendations for these agents.